Developer docs
API playgroundTry for free, no card

Search company profiles

AmbioPharm

Full company profile

uuid0005y9e

Namestring
AmbioPharm
Legal namestring
AmbioPharm Inc.
Websiteurl
ambiopharm.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

AmbioPharm is a privately held peptide-focused contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in North Augusta, South Carolina, with a second manufacturing campus in Shanghai, China. The company specializes in custom peptide-based active pharmaceutical ingredients (APIs), providing custom synthesis, process development, scale-up, and cGMP manufacturing services to pharmaceutical and biotech clients across preclinical, clinical, and commercial stages. Revenue is generated through project-based B2B contracts priced via quote on the basis of sequence complexity, scale (grams to multi-kilograms), purity specifications, and regulatory tier, with direct enterprise sales engagement across North America, Europe, and Asia and no use of distributors or consultants.

The core technology platform is built around solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and a proprietary hybrid synthesis approach that combines SPPS fragment synthesis with LPPS fragment assembly, enabling efficient production of long peptides such as GLP-1 agonists (~39 amino acids) that are difficult to manufacture via linear SPPS alone. AmbioPharm has integrated licensed CEM microwave peptide synthesizers (Liberty Blue for non-GMP and Liberty PRO for GMP up to 15L) along with patented CarboMAX coupling chemistry and one-pot combined coupling/deprotection processes to reduce synthesis time and solvent use. Purification and finishing infrastructure includes HPLC columns up to 100cm (40 kg/batch), lyophilization capacity up to 1,000L at the US site, reactors up to 5,000L in Shanghai, and reported annual production capacity up to one metric ton in the US and 8+ metric tons added by the Shanghai expansion. The workforce includes 500+ chemists and industry professionals with 200+ years of cumulative GMP manufacturing experience, and both facilities carry FDA-inspected status with multiple successful inspections.

Customer segments include large pharmaceutical companies (with named exposure to Eli Lilly, Novo Nordisk), biotech firms (Viking Therapeutics, Apellis Pharmaceuticals), clinical research labs, and adjacent verticals such as cosmetics and peptide vaccines. In May 2026, CordenPharma, owned by private equity firm Astorg, announced the acquisition of AmbioPharm as part of a €900M investment program to scale peptide API capacity for the GLP-1 and weight-loss drug market, with AmbioPharm shareholders reinvesting in the combined entity. The transaction is subject to customary closing conditions.

Short descriptiontext

AmbioPharm is a US-headquartered peptide CDMO founded in 2005 that provides custom peptide API manufacturing to pharmaceutical and biotech companies. It operates FDA-inspected facilities in South Carolina and Shanghai, using proprietary hybrid synthesis and microwave SPPS technology to produce long peptides including GLP-1 agonists.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNorth Augusta, United States
HQ citystring
North Augusta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide API manufacturing, contract development manufacturing, custom peptide synthesis, cGMP peptide production, hybrid peptide synthesis
Industry1 code
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing (Peptide CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

Provides peptide API manufacturing services to pharmaceutical and biotech companies across preclinical through commercial stages. Revenue generated through project-based contracts for custom peptide synthesis, process development, and GMP manufacturing.

ambiopharm.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Project-based custom manufacturing quotes
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing; no standard tiers publicly disclosed. Cost varies based on peptide length, sequence complexity, scale (gram to multi-kilogram), purity requirements, and GMP vs non-GMP specifications.

ambiopharm.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AmbioPharm is a global peptide Contract Development and Manufacturing Organization (CDMO) that develops and manufactures custom peptide Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. It operates two manufacturing facilities (North Augusta, South Carolina, USA and Shanghai, China) using solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and a proprietary hybrid synthesis platform to deliver GMP and non-GMP peptide manufacturing services from preclinical through commercial scale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3-4x reduction in process mass intensity (PMI) compared to linear SPPS
+3 more records
Product overview1 text field

AmbioPharm is a global peptide CDMO (Contract Development and Manufacturing Organization) specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial scales. The company operates as a unified platform combining GMP Manufacturing Services with Custom Peptide Synthesis, Custom Organic Synthesis, Biologically Active Peptides, Non-GMP Services, Vaccine Services, Cosmetic Peptides, and Analytical Development & Validation Services. Key technology capabilities include Microwave SPPS Technology (using CEM equipment), Hybrid Synthesis (combining SPPS and LPPS), and Downstream Processing for purification and isolation. The company operates two major manufacturing facilities in North Augusta, South Carolina and Shanghai, China, offering end-to-end peptide manufacturing from preclinical through commercial production.

Product and service1 record
1GMP Manufacturing Services
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

CordenPharma acquired AmbioPharm to expand peptide API manufacturing capacity. The acquisition adds two facilities (South Carolina and Shanghai), ~400 employees, and complementary upstream/downstream peptide synthesis capabilities including SPPS, LPPS, hybrid synthesis, and TAPS platform. Transaction backed by private equity firm Astorg.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership for microwave peptide synthesis technology. AmbioPharm uses CEM's Liberty Blue (non-GMP) and Liberty PRO (GMP up to 15L) microwave synthesizers, CarboMAX coupling technology, and one-pot combined coupling/deprotection processes. Technology enables rapid process development and production efficiency.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership for Icatibant development and manufacturing. AmbioPharm worked with Adalvo on synthesis and manufacturing of this complex injectable peptide product, which was successfully launched in 14 markets as an affordable version of Firazyr for hereditary angioedema (HAE) treatment.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with UC Davis researchers on non-opioid peptide-based pain therapeutics. AmbioPharm synthesizes designed venom peptides (from Peruvian green velvet tarantula) targeting Nav1.7 voltage-gated ion channels for pain treatment, supported by NIH initiative.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss-based global leader in peptide API CDMO services, including custom peptide synthesis at commercial scale. Directly competes with AmbioPharm in SPPS, LPPS, and hybrid peptide manufacturing, serving the same pharmaceutical and biotech customers (e.g., Lilly, Novo Nordisk). AmbioPharm's SVP of Sales Asia previously held leadership roles at Bachem.

TypeDirect peer
Description

Specialty CDMO focused exclusively on peptide and oligonucleotide API manufacturing for pharma and biotech. Direct head-to-head competitor with AmbioPharm in custom peptide synthesis, GMP manufacturing, and analytical services across clinical and commercial scales.

TypeBroad incumbent
Description

Global full-service CDMO owned by Astorg that announced the acquisition of AmbioPharm in May 2026. CordenPharma offers integrated peptide, lipid nanoparticle, sterile fill-finish, and small molecule services; the acquisition positions CordenPharma as AmbioPharm's parent and largest comparable platform.

TypeBroad incumbent
Description

Largest global CDMO with peptide and oligonucleotide capabilities, serving pharma and biotech from clinical to commercial scale. Overlaps with AmbioPharm in custom peptide API manufacturing but operates across a much broader service portfolio (biologics, cell therapy, small molecules).

TypeBroad incumbent
Description

China-based global CDMO with growing peptide and oligonucleotide capabilities. Comparable to AmbioPharm in offering custom peptide synthesis and GMP manufacturing at scale, though WuXi's primary focus is biologics and broader small molecule CDMO.

TypeEmerging player
Description

Hong Kong/US biotech services company with peptide synthesis and biologics manufacturing capabilities. Direct overlap with AmbioPharm in custom peptide API services, including non-GMP and GMP scale. AmbioPharm's Principal Researcher previously worked at GenScript Nanjing.

TypeBroad incumbent
Description

Global CDMO offering peptide, antibody-drug conjugate, and sterile injectable manufacturing. Comparable to AmbioPharm in peptide API CDMO services, though Piramal operates across a broader range of dosage forms and customer segments.

8Senn Chemicals
TypeDirect peer
Description

Swiss-based specialty peptide manufacturer offering custom peptide synthesis, GMP manufacturing, and amino acid building blocks. Closely comparable niche competitor focused exclusively on peptides at clinical and commercial scale.

TypeBroad incumbent
Description

Global testing and CDMO services group with peptide and small molecule API manufacturing offerings. Overlaps with AmbioPharm in custom peptide synthesis and GMP manufacturing, though peptides are one of many CDMO categories within Eurofins' broad portfolio.

TypeEmerging player
Description

Japanese chemical and life science company with peptide synthesis reagents and custom peptide manufacturing services. Comparable to AmbioPharm in serving Asian pharma customers with peptide APIs, though smaller scale and primarily a reagent supplier.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AmbioPharm

Pharmaceutical Contract Manufacturing (Peptide CDMO)ambiopharm.com

AmbioPharm is a US-headquartered peptide CDMO founded in 2005 that provides custom peptide API manufacturing to pharmaceutical and biotech companies. It operates FDA-inspected facilities in South Carolina and Shanghai, using proprietary hybrid synthesis and microwave SPPS technology to produce long peptides including GLP-1 agonists.

What AmbioPharm does

AmbioPharm is a privately held peptide-focused contract development and manufacturing organization (CDMO) founded in 2005 and headquartered in North Augusta, South Carolina, with a second manufacturing campus in Shanghai, China. The company specializes in custom peptide-based active pharmaceutical ingredients (APIs), providing custom synthesis, process development, scale-up, and cGMP manufacturing services to pharmaceutical and biotech clients across preclinical, clinical, and commercial stages. Revenue is generated through project-based B2B contracts priced via quote on the basis of sequence complexity, scale (grams to multi-kilograms), purity specifications, and regulatory tier, with direct enterprise sales engagement across North America, Europe, and Asia and no use of distributors or consultants.

The core technology platform is built around solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and a proprietary hybrid synthesis approach that combines SPPS fragment synthesis with LPPS fragment assembly, enabling efficient production of long peptides such as GLP-1 agonists (~39 amino acids) that are difficult to manufacture via linear SPPS alone. AmbioPharm has integrated licensed CEM microwave peptide synthesizers (Liberty Blue for non-GMP and Liberty PRO for GMP up to 15L) along with patented CarboMAX coupling chemistry and one-pot combined coupling/deprotection processes to reduce synthesis time and solvent use. Purification and finishing infrastructure includes HPLC columns up to 100cm (40 kg/batch), lyophilization capacity up to 1,000L at the US site, reactors up to 5,000L in Shanghai, and reported annual production capacity up to one metric ton in the US and 8+ metric tons added by the Shanghai expansion. The workforce includes 500+ chemists and industry professionals with 200+ years of cumulative GMP manufacturing experience, and both facilities carry FDA-inspected status with multiple successful inspections.

Customer segments include large pharmaceutical companies (with named exposure to Eli Lilly, Novo Nordisk), biotech firms (Viking Therapeutics, Apellis Pharmaceuticals), clinical research labs, and adjacent verticals such as cosmetics and peptide vaccines. In May 2026, CordenPharma, owned by private equity firm Astorg, announced the acquisition of AmbioPharm as part of a €900M investment program to scale peptide API capacity for the GLP-1 and weight-loss drug market, with AmbioPharm shareholders reinvesting in the combined entity. The transaction is subject to customary closing conditions.

AmbioPharm firmographics

Firmographics
Name
AmbioPharm
Legal name
AmbioPharm Inc.
Website
https://ambiopharm.com
Company type
Private
Founded year
2005
Operating status
Acquired
Headcount range
101–250 employees
Short description
AmbioPharm is a US-headquartered peptide CDMO founded in 2005 that provides custom peptide API manufacturing to pharmaceutical and biotech companies. It operates FDA-inspected facilities in South Carolina and Shanghai, using proprietary hybrid synthesis and microwave SPPS technology to produce long peptides including GLP-1 agonists.
Ownership category
akta.pro rank

AmbioPharm industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (Peptide CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Peptide API manufacturing
  • Contract development manufacturing
  • Custom peptide synthesis
  • CGMP peptide production
  • Hybrid peptide synthesis

Where AmbioPharm is headquartered

Location

Headquarters

HQ city
North Augusta
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AmbioPharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO): Provides peptide API manufacturing services to pharmaceutical and biotech companies across preclinical through commercial stages. Revenue generated through project-based contracts for custom peptide synthesis, process development, and GMP manufacturing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based custom manufacturing quotes

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

AmbioPharm product offering

Product offering

Core offering

AmbioPharm is a global peptide Contract Development and Manufacturing Organization (CDMO) that develops and manufactures custom peptide Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. It operates two manufacturing facilities (North Augusta, South Carolina, USA and Shanghai, China) using solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and a proprietary hybrid synthesis platform to deliver GMP and non-GMP peptide manufacturing services from preclinical through commercial scale.

Product overview

AmbioPharm is a global peptide CDMO (Contract Development and Manufacturing Organization) specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial scales. The company operates as a unified platform combining GMP Manufacturing Services with Custom Peptide Synthesis, Custom Organic Synthesis, Biologically Active Peptides, Non-GMP Services, Vaccine Services, Cosmetic Peptides, and Analytical Development & Validation Services. Key technology capabilities include Microwave SPPS Technology (using CEM equipment), Hybrid Synthesis (combining SPPS and LPPS), and Downstream Processing for purification and isolation. The company operates two major manufacturing facilities in North Augusta, South Carolina and Shanghai, China, offering end-to-end peptide manufacturing from preclinical through commercial production.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMP Manufacturing Services

Quantifiable outcome

  • 3-4x reduction in process mass intensity (PMI) compared to linear SPPS
  • +3 more outcomes

Companies that use AmbioPharm

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

AmbioPharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AmbioPharm partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, major and minor.

  • CordenPharmacoreStrategic or Co-development Partner · 27 May 2026CordenPharma acquired AmbioPharm to expand peptide API manufacturing capacity. The acquisition adds two facilities (South Carolina and Shanghai), ~400 employees, and complementary upstream/downstream peptide synthesis capabilities including SPPS, LPPS, hybrid synthesis, and TAPS platform. Transaction backed by private equity firm Astorg.
  • CEM CorporationcoreTechnology or IntegrationPartnership for microwave peptide synthesis technology. AmbioPharm uses CEM's Liberty Blue (non-GMP) and Liberty PRO (GMP up to 15L) microwave synthesizers, CarboMAX coupling technology, and one-pot combined coupling/deprotection processes. Technology enables rapid process development and production efficiency.
  • AdalvomajorStrategic or Co-development PartnerStrategic partnership for Icatibant development and manufacturing. AmbioPharm worked with Adalvo on synthesis and manufacturing of this complex injectable peptide product, which was successfully launched in 14 markets as an affordable version of Firazyr for hereditary angioedema (HAE) treatment.
  • UC DavisminorStrategic or Co-development PartnerCollaboration with UC Davis researchers on non-opioid peptide-based pain therapeutics. AmbioPharm synthesizes designed venom peptides (from Peruvian green velvet tarantula) targeting Nav1.7 voltage-gated ion channels for pain treatment, supported by NIH initiative.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

AmbioPharm competitors and assessment

Company assessment

Direct peers

  • Bachem: Swiss-based global leader in peptide API CDMO services, including custom peptide synthesis at commercial scale. Directly competes with AmbioPharm in SPPS, LPPS, and hybrid peptide manufacturing, serving the same pharmaceutical and biotech customers (e.g., Lilly, Novo Nordisk). AmbioPharm's SVP of Sales Asia previously held leadership roles at Bachem.
  • PolyPeptide Group: Specialty CDMO focused exclusively on peptide and oligonucleotide API manufacturing for pharma and biotech. Direct head-to-head competitor with AmbioPharm in custom peptide synthesis, GMP manufacturing, and analytical services across clinical and commercial scales.
  • Senn Chemicals: Swiss-based specialty peptide manufacturer offering custom peptide synthesis, GMP manufacturing, and amino acid building blocks. Closely comparable niche competitor focused exclusively on peptides at clinical and commercial scale.

Broad incumbents

  • CordenPharma: Global full-service CDMO owned by Astorg that announced the acquisition of AmbioPharm in May 2026. CordenPharma offers integrated peptide, lipid nanoparticle, sterile fill-finish, and small molecule services; the acquisition positions CordenPharma as AmbioPharm's parent and largest comparable platform.
  • Lonza: Largest global CDMO with peptide and oligonucleotide capabilities, serving pharma and biotech from clinical to commercial scale. Overlaps with AmbioPharm in custom peptide API manufacturing but operates across a much broader service portfolio (biologics, cell therapy, small molecules).
  • WuXi AppTec / WuXi Biologics: China-based global CDMO with growing peptide and oligonucleotide capabilities. Comparable to AmbioPharm in offering custom peptide synthesis and GMP manufacturing at scale, though WuXi's primary focus is biologics and broader small molecule CDMO.
  • Piramal Pharma Solutions: Global CDMO offering peptide, antibody-drug conjugate, and sterile injectable manufacturing. Comparable to AmbioPharm in peptide API CDMO services, though Piramal operates across a broader range of dosage forms and customer segments.
  • Eurofins Scientific CDMO: Global testing and CDMO services group with peptide and small molecule API manufacturing offerings. Overlaps with AmbioPharm in custom peptide synthesis and GMP manufacturing, though peptides are one of many CDMO categories within Eurofins' broad portfolio.

Emerging players

  • GenScript Biotech: Hong Kong/US biotech services company with peptide synthesis and biologics manufacturing capabilities. Direct overlap with AmbioPharm in custom peptide API services, including non-GMP and GMP scale. AmbioPharm's Principal Researcher previously worked at GenScript Nanjing.
  • Tosoh Bioscience (Tosoh Corporation): Japanese chemical and life science company with peptide synthesis reagents and custom peptide manufacturing services. Comparable to AmbioPharm in serving Asian pharma customers with peptide APIs, though smaller scale and primarily a reagent supplier.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AmbioPharm social profiles

Digital presence

AmbioPharm compliance and trust

Trust signal

Compliance2 records

AmbioPharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AmbioPharm leadership team

Management profile

Number of profiles

Profiles5 records

AmbioPharm funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AmbioPharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmbioPharm

What does AmbioPharm do?

AmbioPharm is a global peptide Contract Development and Manufacturing Organization (CDMO) that develops and manufactures custom peptide Active Pharmaceutical Ingredients (APIs) for pharmaceutical and biotech companies. It operates two manufacturing facilities (North Augusta, South Carolina, USA and Shanghai, China) using solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and a proprietary hybrid synthesis platform to deliver GMP and non-GMP peptide manufacturing services from preclinical through commercial scale.

Is AmbioPharm a public or private company?

AmbioPharm is a private company. It is classified as private equity controlled and is currently acquired.

When was AmbioPharm founded?

AmbioPharm was founded in 2005. It employs 101 to 250 people.

Where is AmbioPharm based?

AmbioPharm is headquartered in North Augusta, United States, in the North America region.

How does AmbioPharm make money?

One revenue line is on record: contract Development and Manufacturing (CDMO).

Who are AmbioPharm's main competitors?

Direct peers on record are Bachem, PolyPeptide Group and Senn Chemicals. Broad incumbents are CordenPharma, Lonza, WuXi AppTec / WuXi Biologics, Piramal Pharma Solutions and Eurofins Scientific CDMO. Emerging players are GenScript Biotech and Tosoh Bioscience (Tosoh Corporation).

Does AmbioPharm have an API?

No public API is recorded for AmbioPharm.

What industry is AmbioPharm in?

AmbioPharm's product category is Pharmaceutical Contract Manufacturing (Peptide CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACCordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of GrowthCordenPharma appointed Dr. Jean-Luc Herbeaux as CEO effective 1 October 2026, succeeding Dr. Michael Quirmbach, who will remain as Board Member and Senior Advisor. Herbeaux joins from Hovione, where he served as CEO for over four years. The transition follows 12 years of growth under Quirmbach, including revenue growth from €245 million to over €1 billion.NewswireCordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of GrowthCordenPharma appointed Dr. Jean-Luc Herbeaux as CEO effective 1 October 2026, succeeding Dr. Michael Quirmbach, who will become Board Member and Senior Advisor. Herbeaux brings experience from Hovione, and the transition follows 12 years of growth under Quirmbach, including revenue growth from €245 million to over €1 billion.SWI swissinfo.chWhat’s behind the peptide boom and why it matters to SwitzerlandSamsung Biologics agreed to acquire Swiss peptide manufacturer PolyPeptide for about CHF1.46 billion, the largest M&A deal by a South Korean biopharmaceutical company. PolyPeptide produces one-third of commercially approved peptides, and Swiss firms like Bachem hold over 12% of global peptide manufacturing capacity. The FDA may soon allow compounding of six peptides, potentially boosting demand.PrtimesPeptide Therapeutics Market to Hit USD 342.31 Million by 2032 (8.73% CAGR) – PR TimesThe peptide therapeutics market is projected to grow from USD 190 million in 2025 to USD 342 million by 2032, representing an 8.73% CAGR during the 2026–2032 forecast period, driven by GLP-1 regulatory approvals and accelerating clinical-to-commercial transitions. The 2026 strategic window is characterized by tight global GMP manufacturing capacity, with the top five industry participants controlling approximately 65% of identifiable capacity, creating a concentrated competitive landscape that favors players with scale and integrated capabilities. Key strategic moves include CordenPharma's acquisition of AmbioPharm in mid-2026 and Bachem's expansion of North American cGMP capacity in 2025, as companies seek to secure supply chains and mitigate capacity constraints for complex peptide manufacturing.AstorgAstorg-backed CordenPharma acquires AmbioPharm, strengthening its position as a leading global peptide development and manufacturing platform - AstorgAstorg's portfolio company CordenPharma is acquiring US-based AmbioPharm, a peptide API CDMO with facilities in the US and China, to strengthen its global manufacturing capabilities in peptides. The acquisition increases CordenPharma's production footprint and technical expertise, supporting the growing demand for peptide-based therapeutics. This move is part of CordenPharma's strategy to expand its presence across three continents and accelerate growth in the peptide market.Pulse 2.0CordenPharma Acquires AmbioPharm To Expand Global Peptide API CapacityCordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO), to strengthen its peptide manufacturing capabilities and expand its global production footprint. AmbioPharm operates facilities in North Augusta, South Carolina, and Shanghai, China, employing approximately 400 people and adding complementary upstream and downstream peptide synthesis capabilities including SPPS, LPPS, hybrid synthesis, and CordenPharma's TAPS platform. Financial terms were not disclosed, and the transaction remains subject to customary closing conditions; AmbioPharm shareholders will reinvest in the combined company, reflecting confidence in growth potential of the expanded peptide platform.BioSpaceCordenPharma inks AmbioPharm buyout to continue peptide production expansionBasel-based CordenPharma has struck a deal to acquire AmbioPharm, expanding its peptide development and manufacturing capabilities with facilities in South Carolina and Shanghai employing about 400 people. The acquisition adds significant capacity for purification and lyophilization of peptide active pharmaceutical ingredients, complementing CordenPharma's existing Colorado plant and bringing its total network to 11 European and North American sites. The deal is backed by private equity firm Astorg and forms part of CordenPharma's previously announced €900 million investment plan to strengthen its position in the growing GLP-1 and weight-loss drug manufacturing market.InvestorsinhealthcareSwitzerland: CordenPharma expands global peptides platform in US and ChinaCordenPharma agreed to acquire AmbioPharm, a US-based peptide API CDMO, from Carlyle. The deal expands CordenPharma's global facility network of 11 sites in Europe and North America.PR NewswireCordenPharma acquisisce AmbioPharm per espandere la capacità globale delle API peptidicheCordenPharma, a Swiss-based global CDMO, has signed an agreement to acquire AmbioPharm, a US-based peptide API contract development and manufacturing organization with facilities in North Augusta, South Carolina (USA) and Shanghai, China. The acquisition adds approximately 400 employees across two sites, expanding CordenPharma's peptide manufacturing capacity with purification and lyophilization capabilities in the US and upstream production capabilities in Shanghai. Financial terms were not disclosed, and the transaction is subject to customary closing conditions.Pulse 2.0CordenPharma Acquires AmbioPharm To Expand Global API Manufacturing CapacityCordenPharma, a global contract development and manufacturing organization (CDMO), has agreed to acquire peptide API CDMO AmbioPharm, which operates manufacturing facilities in South Carolina and Shanghai, China. The acquisition adds CordenPharma's second U.S. peptide manufacturing site and significant upstream synthesis capabilities in China, with approximately 400 employees joining the combined company. The transaction expands CordenPharma's global network to 13 sites across three continents and strengthens its end-to-end peptide development and manufacturing platform, with financial terms undisclosed and closing subject to customary conditions.